Andrew Yale, PhD

Andrew Yale, PhD has a wide range of work experience in the scientific field. From 2021 to present, they have been a Postdoctoral Research Scientist at Zymo Research Corp. From 2014 to 2021, they were a Postdoctoral Researcher at UC Irvine, where they studied the relationship between protein glycosylation and temozolomide (TMZ) drug resistance in glioblastoma. Andrew also worked as a Doctoral Candidate in the Flanagan Lab at UC Irvine, where they studied how protein glycosylation could impact electrophysiological characteristics and fate bias of neural stem cells. From 2011 to 2012, they were an Undergraduate Researcher at California State University, Fullerton, where they studied how the extracellular matrix (ECM) component microfibril-associated glycoprotein 2 (MAGP2) contributes to ovarian cancer function. Andrew also worked as an Undergraduate Research Assistant at University of California, Irvine from 2012-2013.

Andrew Yale, PhD obtained a Bachelor of Science (B.S.) in Cellular and Molecular Biology from California State University, Fullerton in 2013. Andrew then went on to obtain a Doctor of Philosophy (Ph.D.) in Stem Cell Biology from UC Irvine in 2020.